| RRC ID |
87365
|
| 著者 |
Tan GYT, Lin PY, Cheng LT, Tsai Yuan YS, Huang SH, Yu CA, Chen CT, Chi P, Hwang-Verslues WW.
|
| タイトル |
BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC).
|
| ジャーナル |
EMBO Mol Med
|
| Abstract |
Ovarian clear cell carcinomas (OCCC), particularly cases that retain wild-type AT-rich interactive domain 1 A (ARID1A) expression (approximately 50% of the OCCC cases), are chemoresistant and lack specific therapies. We identified BMAL2 as a critical OCCC oncogene that promotes tumorigenesis by preventing endogenous DNA damage. BMAL2 depletion altered the expression of genes encoding DNA damage repair proteins, including RAD51, a core enzyme of the homologous recombination (HR) pathway. This led to DNA double-stranded break accumulation, decreased cell viability and reduced tumor growth. This dependence on BMAL2 to maintain DNA integrity and cell viability can be a new route to suppress OCCC. Consistent with this idea, we found that GW833972A, a cannabinoid receptor agonist, bound BMAL2 with high affinity and facilitated its protein degradation. This in turn reduced RAD51 expression, leading to an accumulation of DNA damage, decreased cell viability and reduced OCCC tumor growth. GW833972A is effective by itself at high dose and can also be used at lower dosages to enhance the effectiveness of Poly (ADP-ribose) polymerase inhibitor (PARPi) treatments in BMAL2-expressing OCCC. Together, our findings reveal an essential oncogenic role of BMAL2 and demonstrate that it is an appealing therapeutic target, especially for ARID1A-wt OCCC.
|
| 公開日 |
2026-4-3
|
| DOI |
10.1038/s44321-026-00414-8
|
| PII |
10.1038/s44321-026-00414-8
|
| PMID |
41933240
|
| リソース情報 |
| ヒト・動物細胞 |
JHOC-5(RCB1520)
JHOC-9(RCB2226) |
